• Sanjiv J Shah, Ted Feldman, Mark J Ricciardi, Rami Kahwash, Scott Lilly, Sheldon Litwin, Chris D Nielsen, Pim van der Harst, Elke Hoendermis, Martin Penicka, Jozef Bartunek, Peter S Fail, David M Kaye, Anthony Walton, Mark C Petrie, Niki Walker, Anupam Basuray, Steven Yakubov, Scott L Hummel, Stanley Chetcuti, Rhondalyn Forde-McLean, Howard C Herrmann, Daniel Burkhoff, Joseph M Massaro, Cleland John G F JGF Robertson Centre for Biostatistics and Clinical Trials, Institute of Health & Well-Being, University of Glasgow, Glasgow, United Kingdom. , and Laura Mauri.
• Northwestern University Feinberg School of Medicine, Chicago, Illinois.
• JAMA Cardiol. 2018 Oct 1; 3 (10): 968-977.

ImportanceIn patients with heart failure (HF) and left ventricular ejection fraction (LVEF) equal to or greater than 40%, a transcatheter interatrial shunt device (IASD; Corvia Medical) reduces exercise pulmonary capillary wedge pressure (PCWP) and is safe compared with sham control treatment at 1 month of follow-up. The longer-term safety and patency of the IASD has not yet been demonstrated in the setting of a randomized clinical trial (RCT).ObjectiveTo evaluate the 1-year safety and clinical outcomes of the IASD compared with a sham control treatment.Design, Setting, And ParticipantsThis phase 2, double-blind, 1-to-1 sham-controlled multicenter RCT of IASD implantation vs a sham procedure (femoral venous access and imaging of the interatrial septum without IASD) was conducted in 22 centers in the United States, Europe, and Australia on patients with New York Heart Association (NYHA) class III or ambulatory class IV HF, LVEF equal to or greater than 40%, exercise PCWP equal to or greater than 25 mm Hg, and PCWP-right atrial pressure gradient equal to or greater than 5 mm Hg.Main Outcomes And MeasuresSafety was assessed by major adverse cardiac, cerebrovascular, or renal events (MACCRE). Exploratory outcomes evaluated at 1 year were hospitalizations for HF, NYHA class, quality of life, a 6-minute walk test, and device patency.ResultsAfter 1 year, shunts were patent in all IASD-treated patients; MACCRE did not differ significantly in the IASD arm (2 of 21 [9.5%]) vs the control arm (5 of 22 [22.7%]; P = .41), and no strokes occurred. The yearly rate of hospitalizations for HF was 0.22 in the IASD arm and 0.63 in the control arm (P = .06). Median improvement in NYHA class was 1 class in the IASD arm (IQR, -1 to 0) vs 0 in the control arm (IQR, -1 to 0; P = .08). Quality of life and 6-minute walk test distance were similar in both groups. At 6 months, there was an increase in right ventricular size in the IASD arm (mean [SD], 7.9 [8.0] mL/m2) vs the control arm (-1.8 [9.6] mL/m2; P = .002), consistent with left-to-right shunting through the device; no further increase occurred in the IASD arm at 12 months.Conclusions And RelevanceThe REDUCE LAP-HF I phase 2, sham-controlled RCT confirms the longer-term patency of the IASD. Through 1 year of follow-up, IASD treatment appears safe, with no significant differences in MACCRE in patients receiving IASD compared with those who received sham control treatment.Trial RegistrationClinicalTrials.gov identifier: NCT02600234.

21 keywords...

hide…